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Abstract: Intensive research over recent years has provided irrefutable evidence of links between obesity and the risk of 
an increasing number of human cancers. The predicted economic burden is causing significant concern. This has 
prompted investigation of the underlying mechanisms with a focus on deregulated metabolic pathways. A number of 
metabolic processes and associated signalling pathways are associated with the development of obesity. These include a 
number of interlinking pathways regulating endocrine, redox, inflammation, immunity and lipogenic processes. The 
identification of deregulated metabolic pathways in obesity with promotion of carcinogenesis has targeted research on the 
signalling molecules involved. Consequently this mini review is focused on aberrant signalling of deregulated pathways 
provoked by diets that lead to obesity and their role in carcinogenesis. Knowledge of the signalling molecules involved 
will assist in directing and establishing dietary manipulation strategies to restore metabolic health in obese individuals. 
Importantly the identified diversity of signalling pathways linked to obesity related cancers will permit design of more 
effective combinatorial and multi-targeted cancer therapies in the future.  
Keywords: Obesity related cancer, metabolic signalling, signalling pathways 
INTRODUCTION 
 The 2007 World Cancer Research Fund/American 
Institute for Cancer Research (WCRF/AICR) report [1] 
unequivocally endorsed links between obesity and increased 
risk of cancer. The global scale of the current obesity 
epidemic is causing significant concern as the projected rise 
in co-morbidities such as cancer are accompanied by 
increased economic and social burdens [2-4]. This has 
prompted intense research efforts to establish the 
determinants of increased cancer risk associated with 
obesity. Consequently substantial evidence has emerged 
establishing links between obesity and colorectal, kidney, 
liver/gall bladder, pancreatic, oesophageal, stomach, 
prostate, postmenopausal breast, endometrial, uterine and 
ovarian cancers, summarised in update reports from 
WCRF/AICR [5-7]. Accumulating evidence indicates that 
dietary factors such as consumption of excess calories, fat 
and sugars, together with sedentary behaviour and associated 
low energy expenditure are associated with increased cancer 
risk [1] (Fig. 1). Conversely, reduced calorie intake and 
increased fruit, vegetable and fibre intake have been linked 
to reduced cancer risk [1] (Fig. 1). Research on the 
physiological changes caused by the dietary and lifestyle 
trends leading to obesity has directed close scrutiny of 
associated deregulated signalling pathways to identify links 
with carcinogenesis [8-13]. Obesity is characterised by  
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profound metabolic deregulation of signalling pathways that 
are essential to maintain homeostatic control of biological 
processes in cells and tissues [14-18]. Homeostatic control is 
fundamental in preventing the aberrant signalling that is a 
distinguishing characteristic of cancer cells. This review will 
examine the evidence linking signalling of the endocrine 
system [14, 15, 17]; redox regulation [19-21]; inflammatory 
and immune responses [16, 22-25] and lipogenesis [26] that 
are deregulated in obesity and linked to increased cancer risk 
(Fig. 2). The identification of signalling pathways linking 
obesity with cancer present novel targets and strategies to 
break the obesity cancer link.  
ADIPOKINE SIGNALLING PATHWAYS 
IMPLICATED IN CANCER 
 Adipose tissue, the body’s largest endocrine organ [27, 
28], demonstrates significant deregulation of homeostatic 
control in response to consumption of high energy diets and 
obesity. Levels of adipose derived hormones and cytokines 
are altered [14, 29-31]. Two of the most abundant adipose 
hormones, leptin and adiponectin, regulate energy 
homeostasis [32]. Obesity is characterised by increased 
leptin and decreased adiponectin in serum with implications 
for a role as potential mediators in carcinogenesis linked to 
obesity [33-36].  
 The intracellular signalling leptin receptor, ObRb, is 
expressed in several tissues (colon, oesophageal, breast) 
associated with increased cancer risk linked to obesity [33-
38] and altered levels in tumours have been reported to have 
clinical implications [33, 35, 36, 38-41]. Roles in stimulation 
of cell proliferation, anti-apoptotic activity and inflammation 
have been demonstrated [11, 13, 42, 43]. Leptin regulates 
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several signalling pathways, JAK/STAT3 (Janus 
kinase/signal transducer and activator of transcription 3), 
PI3K/Akt (phosphatidylinositol-4,5-bisphosphate 3-kinase/v-
akt murine thymoma viral oncogene homolog), mTOR 
(mammalian target of rapamycin) and MAPK (mitogen-
activated protein kinase), that present targets for modulation 
of carcinogenesis. Leptin is also linked to inflammatory and 
immune responses [13,36,44], activating a number of 
inflammatory cytokines associated with cancer. Leptin 
induced cytokines such as CXCL1 (chemokine CXC motif 
ligand 1) [13,41] and vascular perturbations leading to 
elevated VEGF (vascular endothelial growth factor) may be 
important in angiogenesis required for tumour growth [45]. 
 Adiponectin is an abundant adipokine that is decreased 
with increased visceral obesity [15, 17]. There are two 
adiponectin receptors, ADIPOR1 and ADIPOR2, mediating 
signalling of full-length adiponectin and the truncated 
 
Fig. (1). Diet and lifestyle factors associated with obesity and increased cancer risk. Consumption of high energy diets, sendentary behaviour 
and increased age promote obesity and increased risk of cancer. Conversely, reduced calorie intake and increased fruit, vegetable and fibre 
intake have been linked to reduced obesity and cancer risk.
 
Obesity is characterised by profound metabolic deregulation of signalling 
pathways, including those associated with the endocrine system, redox regulation, inflammation, immune responses and lipogenesis that are 
essential to maintain homeostatic control of biological processes in cells and tissues.
 
Loss of homeostatic control leads to aberrant signalling 
that has similarities with the distinguishing characteristics of cancer cells.  
 
Fig. (2). Signalling pathways implicated in obesity associated cancers. Obesity leads to elevated insulin, leptin, oestrogen levels and 
activation of associated receptor signalling. In parallel adiponectin levels fall with concomitant reduction in adiponectin signalling. Obesity 
and associated deregulation of signalling pathways leads to systemic and intracellular elevation of pro-inflammatory cytokines with 
increased oxidative stress. Deregulation of gene transcription and signalling pathways lead to promotion of cell proliferation and survival. 
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globular portion of adiponectin [46]. These receptors are 
located in tissues prone to obesity related carcinogenesis and 
are expressed by colon and breast cancers [34, 35, 41, 42, 
48]. Adiponectin stimulates phosphorylation of AMPK (5’-
adenosine monophosphate-activated protein kinase) to 
regulate cellular energy metabolism and protein synthesis 
[34]. Adiponectin has been demonstrated in vitro to counter 
leptin induced IL-6 (interleukin-6), NF?B (nuclear factor 
kappa-light-chain-enhancer of activated B cells) and STAT3 
to reduce cell proliferation [12, 47]. Adiponectin is also 
reported to be associated with improved insulin regulation, 
blood glucose and triglyceride levels [48, 49].  
INSULIN AND INSULIN LIKE GROWTH FACTORS 
 Inappropriate glycaemic control is a feature of obesity 
with consequences for development of diabetes and risk of 
developing cancer [50]. Hyperglycaemia in response to 
obesity is associated with hyperinsulinemia and the 
promotion of uncontrolled cell growth associated with 
tumorigenesis [51, 52]. Insulin signalling is initiated via 
transmembrane receptors, insulin (INSR) and insulin growth 
factor (IGF) receptor hybrids (IGF/INSR) to activate 
intracellular signalling cascades that ultimately influence 
gene transcription and cellular processes regulating growth 
and differentiation [53]. Insulin receptors are expressed by 
cells linked to obesity related carcinogenesis and in cancer 
[37, 41]. INSRs activate PI3K/Akt and downstream 
activation of mTOR and, or MAPK to regulate cell growth 
and mitogenesis [52]. Similarly, increased circulating 
insulin-like growth factor-1 (IGF-1) in obese individuals 
activates PI3/Akt and MAPK [52]. IGF-I is also linked to 
increased risk and poor prognosis for several human obesity 
related cancers [54]. Bioavailable IGF-I is increased by 
hyperinsulinemia in obese individuals as a consequence of 
insulin induced decreases in IGF binding proteins [52]. 
Notably, VEGF is also induced by elevated insulin and IGF-I 
levels associated with obesity [55] and aggressive cancers 
[56, 57]. 
STEROID HORMONES 
 Elevated levels of both total and free oestrogens 
produced by adipose tissue are linked with obesity related 
breast cancer [58]. Aromatase, responsible for oestrogen 
biosynthesis, is also elevated with obesity and can further 
influence the impact of oestrogens on carcinogenesis [24]. 
Activation of oestrogen receptors (ER) leads to canonical 
oestrogen response element (ERE)-dependent signalling. 
Oestrogen bound receptors activate EREs in promoter 
regions of target genes inducing transcription of genes 
regulating proliferation and angiogenesis [59]. Non-genomic 
effects following complex of ER with other receptors, such 
as EGFR (epidermal growth factor receptor) and IGR, leads 
to induction of MAPK and PI3K/Akt pathways [60]. In 
addition to oestrogen signalling effects on regulation of cell 
proliferation, mammalian cell metabolism of oestrogen 
generates DNA-reactive metabolites that cause DNA 
mutations associated with carcinogenesis [61]. 
 
 Links between obesity related cancers and the androgen 
hormones are more equivocal. However, there are links 
between obesity and aggressive prostate cancer [62]. This is 
attributed to promiscuous androgen receptor activity between 
androgens and circulating cytokines (IL-6), growth factors 
(IGF, epidermal growth factor) and stimulation of 
JAK/STAT and PI3K/Akt/mTOR promoting cell survival 
and proliferation [63]. 
 There has also been some interest in the extensive 
metabolic effects of glucocorticoids. These hormones are 
increased during calorie restriction and weight reduction [64] 
both factors associated with reduced cancer risk. Glucocor-
ticoids activate glucocorticoid receptors to regulate transcri-
ption of genes intimately involved in regulation of apoptosis 
[15, 65-67]. Cell regulation of apoptosis is crucial in 
preventing carcinogenesis. Another aspect of glucocorticoid 
function is as an anti-inflammatory [68]. The role of 
glucocorticoids in limiting and resolving inflammation [69] 
could potentially be an important pathway linked to obesity 
related cancer. 
OXIDATIVE STRESS, IMMUNITY AND 
INFLAMMATORY FACTORS 
 The cascade of deregulated metabolic pathways deriving 
from over consumption of nutrients and the development of 
obesity ultimately overwhelm redox defences [70]. The 
transcription factor Nrf2 (nuclear factor (erythroid-derived 2)-
like 2) has been identified as a key regulator of redox balance 
[71] and is deregulated in obesity [49]. Deregulation of Nrf2 
regulated gene transcription has implications for a host of 
signaling pathways that are involved in detoxifying 
metabolites and damaged proteins, maintenance of redox 
balance and DNA repair [72]. This has implications for 
carcinogenesis since regulation of these processes is crucial 
to maintaining homeostasis, DNA integrity and cell 
regulation.  
 Deregulation of metabolic pathways and the resultant 
oxidative stress in obesity is associated with activation of 
inflammatory and immune responses [73]. Immune and 
inflammatory responses are intimately linked with 
carcinogenesis [74]. This is characterised by increased NF?B 
activity, inappropriate production of pro-inflammatory 
cytokines, immune cell infiltration and disrupted tissue 
homeostasis [16, 22, 24, 75, 76]. Increases in circulating 
CRP (C-reactive protein), TNF? (tumour necrosis factor 
alpha), IL6, IL1? (interleukin-1 beta) and macrophage 
attractants, such as MCP-1 (monocyte chemotactic protein-1) 
are generated as a consequence of the production of pro-
inflammatory cytokines from excess adipose tissue [77]. 
This exacerbates the deregulated inflammatory and immune 
responses [77]. Cross-talk between insulin, leptin and 
adiponectin pathways are linked to activation of 
inflammatory cytokines associated with carcinogenesis [13, 
78]. Mediation of these responses involves recruitment of 
NF?B, STAT3, c-jun-NH2 terminal protein kinase (JNK) 
pathways [77]. NF?B is recognised as an active player in 
tumour associated aberrant expression of genes involved in 
cell proliferation, apoptosis, angiogenesis and inflammation  
 
Signalling Pathways and Obesity-Related Cancer The Open Obesity Journal, 2014, Volume 6    47 
[79]. It has been noted that insulin stimulated kinases, such 
as atypical PKCs activate NF?B [80, 81]. Atypical PKCs are 
overexpressed in a number of tissues associated with obesity 
related cancers, such as colon, kidney, liver, oesophagus and 
breast [82]. These interlinking pathways further emphasise 
the complexity in the processes of obesity associated 
carcinogenesis and warrant further investigation. 
LIPOGENIC PATHWAYS 
 Obesity is associated with activation of lipogenic 
pathways characterised by elevated levels of fatty acid 
synthase (FASN) [18]. Over expression of FASN is a 
common event in malignancies [26]. Elevated FASN has 
been identified as a prognostic indicator and is linked to 
therapy resistant tumours [83]. Increased lipogenesis via the 
AKT-mTORC1 (mechanistic target of rapamycin complex 1) 
pathway has also been linked to hepatocellular carcinoma 
[84]. While mTORC1, a nutrient and insulin sensor, is also 
emerging as a regulator of lipid homeostasis that may be 
implicated in carcinogenesis [85]. This may be relevant to 
obesity associated liver cancer. Further research in this area 
may also reveal other lipogenic pathways implicated in 
obesity related cancer.  
CONCLUSION 
 The metabolic deregulation associated with obesity 
presents a number of interconnected pathways that have 
implications for carcinogenesis. This knowledge can inform 
on potential strategies to reduce cancer risk and also direct 
investigation of the potential of therapies that restore 
metabolic regulation to improve outcomes for cancer 
patients. A number of studies have demonstrated that 
reducing dietary energy consumption can restore 
homeostatic regulation of metabolic pathways and reduce 
obesity related cancers [54,86-88]. Investigation of the 
presence of receptors for the various signalling molecules 
and hormones deregulated in obesity in tissues prone to 
obesity related cancers may inform about the potential to 
manipulate these signalling pathways to prevent cancer. 
There has been limited study of the potential to influence 
outcomes for cancer patients using therapeutics directed at 
alleviating the disorders associated with the metabolic 
syndrome [89-91]. Diabetic therapies have been linked to 
reduction of some cancers, but not others [90]. Greater 
understanding of the interplay of deregulated metabolic 
pathways in carcinogenesis will be essential in directing 
appropriate and more effective therapeutic strategies for 
individuals and contribute to producing multi-targeted 
approaches to reduce therapy resistance. Thus further studies 
are warranted to determine appropriate strategies to combat 
obesity related cancer and develop novel combination 
therapies and multi-targeted approaches to provide more 
effective treatment of cancer patients. 
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